Nivolumab in patients with advanced renal cell carcinoma in France: interim results of the observational, real-world WITNESS study.
Fiche publication
Date publication
juin 2024
Journal
ESMO open
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BARTHELEMY Philippe, Dr EYMARD Jean-Christophe, Dr SPAETH Dominique, Dr THIERY-VUILLEMIN Antoine, Dr MOUILLET Guillaume
Tous les auteurs :
Barthélémy P, Albigès L, Escudier B, Narciso B, Bigot P, Chehimi M, Emambux S, Calcagno F, Mouillet G, Eymard JC, Schlürmann F, Bailly S, Garbay D, Berdah JF, Palmaro MB, Goupil MG, Spaeth D, Néré S, Quentric C, Vano YA, Thiery-Vuillemin A
Lien Pubmed
Résumé
Nivolumab is the first immune checkpoint inhibitor approved in Europe for the treatment of advanced renal cell carcinoma (aRCC) in patients resistant to prior antiangiogenic therapy. WITNESS is an ongoing, prospective, observational study designed to evaluate the effectiveness and safety of nivolumab in patients with aRCC treated in real life (or routine practice) in France (ClinicalTrials.gov identifier: NCT03455452).
Mots clés
advanced renal cell carcinoma, effectiveness, metastases, nivolumab, real-world data, safety
Référence
ESMO Open. 2024 06 18;9(7):103602